AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis

 AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis

AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis

Shots:

  • The company submitted applications to the US FDA & EMA seeking approval for Rinvoq (upadacitinib) for adults (15mg/30mg, qd) and adolescents (15mg, qd) with moderate to severe AD. The submission is based on three pivotal P-III studies and was studied without TCS in Measure Up 1 and Measure Up 2 and with TCS in AD Up
  • Results: Rinvoq demonstrated an improvement in skin clearance and reduction in itch in adults and adolescents, met its co-1EPs including at least a 75% improvement in EASI 75 and a validated (vIGA-AD) score of 0/1 @16wks., no new safety profile in observed
  • Rinvoq is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. The submissions reinforce AbbVie’s commitment to bringing Rinvoq to more patients living with immune-mediated diseases

Click here ­to­ read full press release/ article | Ref: Abbvie | Image: The Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post